Please login to the form below

Not currently logged in
Email:
Password:

BMJ: 'Lilly acted properly'

The British Medical Journal has officially apologised to Eli Lilly & Co for accusing it of hiding side effect data relating to antidepressant, Prozac.

The British Medical Journal (BMJ) has apologised officially to US pharmaceutical company Eli Lilly & Co and has withdrawn certain claims it made over the questionable disclosure of side effect data relating to antidepressant Prozac.

The journal, one of the country's most esteemed publications, alleged in an article published in early January that documentary evidence of what were described as ìtroubling side effectsî linked to Lilly's top-selling antidepressant, had ìgone missingî during a product liability lawsuit in 1994.

The evidence in question was later submitted to the BMJ by a source, who remains anonymous, and the journal in turn submitted it to America's Food and Drug Administration in what some saw as rather atypical behaviour for a publication of its type.

Following a complaint by Lilly, which said it was ìdisturbedî as the article in January ìinaccurately reported about Prozac and made negative references regarding [the] company's conductî, the BMJ conducted a deeper investigation and then retracted the claims.

ìAs a result of a detailed investigation, it is clear that these documents did not go missing. The BMJ is happy to set the record straight and to apologise to Eli Lilly,î it stated. Lilly accepted its apology.

However, despite acting editor Kamran Abbasi's proclamation that ìthe BMJ did not intend to suggest that Eli Lilly caused these documents to go missingî, he remains adamant that other parts of the article are accurate; notably, claims that Lilly was aware of Prozac's ìtroubling side effectsî in the 1980s, and hence the question over whether the alleged ìmissingî documents were submitted to the FDA at the appropriate time is still yet to be answered.

As part of the SSRI (selective serotonin reuptake inhibitor) class of antidepressant medications, Prozac bore a good deal of scrutiny in 2004 when a furore sprang up based on potential links to suicidal behaviour in juvenile patients on withdrawal of medication.

All companies marketing SSRIs were obliged by regulators to make immediate label changes, however GlaxoSmithKline, which makes Seroxat, seemed to bear the brunt of the pressure. Prozac is currently the only such drug approved by the FDA for treating children.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics